The effect of age on outcomes after isolated limb perfusion for advanced extremity malignancies

Isolated limb perfusion (ILP) is a well-established treatment for patients with advanced extremity malignancies unsuitable for limb-conserving surgery. However, little is known about the outcomes of this treatment in elderly patients. We sought to determine the effects of age on the tolerability and...

Full description

Saved in:
Bibliographic Details
Published in:European journal of cancer (1990) 2018-09, Vol.100, p.46-54
Main Authors: Smith, H.G., Wilkinson, M.J., Smith, M.J.F., Strauss, D.C., Hayes, A.J.
Format: Article
Language:English
Subjects:
Age
Age Factors
Aged
Chemotherapy, Cancer, Regional Perfusion - adverse effects
Chemotherapy, Cancer, Regional Perfusion - methods
Chemotherapy, Cancer, Regional Perfusion - mortality
Databases, Factual
Disease Progression
Extremities - blood supply
Female
Geriatric oncology
Geriatrics
Humans
Impact analysis
Isolated limb perfusion
Male
Malignancy
Melanoma
Melanoma - mortality
Melanoma - pathology
Melanoma - therapy
Melphalan - administration & dosage
Melphalan - adverse effects
Morbidity
Mortality
Neoplasm Recurrence, Local
Older people
Pathology
Patients
Perfusion
Progression-Free Survival
Regional Blood Flow
Response rates
Risk Factors
Sarcoma
Sarcoma - drug therapy
Sarcoma - mortality
Sarcoma - pathology
Skin Neoplasms - mortality
Skin Neoplasms - pathology
Skin Neoplasms - therapy
Soft Tissue Neoplasms - drug therapy
Soft Tissue Neoplasms - mortality
Soft Tissue Neoplasms - pathology
Soft-tissue sarcoma
Surgery
Time Factors
Toxicity
Treatment Outcome
Tumor Necrosis Factor-alpha - administration & dosage
Tumor Necrosis Factor-alpha - adverse effects
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Isolated limb perfusion (ILP) is a well-established treatment for patients with advanced extremity malignancies unsuitable for limb-conserving surgery. However, little is known about the outcomes of this treatment in elderly patients. We sought to determine the effects of age on the tolerability and efficacy of ILP for advanced extremity malignancy. Patients undergoing ILP at our institution between January 2005 and January 2018 were identified from a prospectively maintained database. Patients were stratified by pathology (melanoma, soft-tissue sarcoma, other) and age (
ISSN:0959-8049
1879-0852
DOI:10.1016/j.ejca.2018.04.014